Not medical advice. Talk to your provider before using any peptide. Full disclaimer
CJC-1295 (No DAC)
Beginner tier: 100 mcg, daily · 12w on / 4w off · community consensus
Also known as: Mod GRF 1-29, Modified GRF(1-29), GRF(1-29) NH2 (modified)
Zero completed clinical trials for this specific compound, and it's still the most popular GHRH analog in the peptide community. CJC-1295 without DAC (Mod GRF 1-29) is a short-acting growth hormone-releasing hormone analog with a half-life estimated at about 30 minutes. No human study has measured it. It triggers a GH pulse that rises and falls the way your pituitary does on its own, then clears. The 100 mcg dosing convention comes from receptor saturation modeling and community experience across 300 to 600 Reddit threads, not from a clinical trial. Nearly every protocol pairs it with Ipamorelin for a cleaner, stronger pulse.
What Is CJC-1295 (No DAC)?
The community figured this one out before the researchers did. CJC-1295 without DAC, also called Mod GRF 1-29 (parent GRF(1-29) CAS 83930-13-6), is a 29-amino-acid GHRH analog modified at four positions to resist enzymatic breakdown. Its closest human data comes from Corpas et al. (1992)[1], where GHRH(1-29) injected subcutaneously twice daily reversed the low GH and IGF-1 levels of old men.
The mechanism is direct. Mod GRF 1-29 binds the GHRH receptor on pituitary somatotroph cells, triggering a cAMP-driven GH release that peaks around 15 to 30 minutes and clears within the hour. That short action window is the entire point. Unlike the DAC version (which circulates for days and produces tonic GH elevation), the no-DAC form preserves your natural pulsatile rhythm.
Real-world use centers on the Mod GRF + Ipamorelin stack. Community consensus across hundreds of r/Peptides threads and practitioner networks puts the standard protocol at 100 mcg of each, co-injected subcutaneously once or twice daily on a fasted stomach before bed. Users consistently report improved sleep within the first two weeks, faster recovery by week three, and visible body composition changes by month two. Product quality is a known problem; Finnrick Analytics found purity as low as 68.75% across 244 samples from 47 companies. No FDA-approved form exists, and no Phase I, II, or III trial has been completed for Mod GRF 1-29 specifically.
How CJC-1295 (No DAC) Works
Mod GRF 1-29 acts on one receptor, but the downstream cascade is worth understanding. The compound binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. This is a Gs protein-coupled receptor. Binding activates adenylyl cyclase, raises intracellular cAMP, and primes the cell for GH synthesis and exocytosis.
Its half-life has never been measured in people; the community estimate is roughly 30 minutes. The closest human data are for a related D-Ala2 analog (Soule et al.)[2]. Given by IV infusion to 10 men, it cleared with a 6.7-minute half-time. Either way, receptor exposure lasts only a brief window. That brevity produces a sharp GH spike that mimics the body's own pulsatile pattern; somatostatin feedback kicks in and shuts the pulse down naturally.
When paired with Ipamorelin (a ghrelin mimetic acting on GHS-R1a), the two pathways converge on the same somatotroph cell from different directions. GHRH sets the amplitude. The ghrelin signal sets the timing. Community reports describe a combined GH pulse larger than either compound alone. Ipamorelin's selectivity matters here. Unlike GHRP-2 or GHRP-6, it doesn't elevate cortisol, ACTH, or prolactin at standard doses. Downstream, the raised GH pulse drives hepatic IGF-1 production, lipolysis through hormone-sensitive lipase activation, and anabolic signaling in muscle and connective tissue.
CJC-1295 (No DAC) Benefits
- CJC-1295 (No DAC) benefits center on natural GH pulse amplification and the downstream effects that follow.
- Pulsatile GH release that preserves your body's own feedback loops. Unlike the DAC form or exogenous HGH, somatostatin regulation stays intact (Corpas et al. 1992,; analog mechanism confirmed)[1].
- Clean hormonal profile when stacked with Ipamorelin. No cortisol, ACTH, or prolactin elevation at 100 mcg doses; this selectivity is what separates the Ipamorelin pairing from GHRP-2 or GHRP-6 stacks (Raun et al. 1998)[3].
- Improved sleep quality within 1 to 2 weeks. This is the most consistently reported early benefit across community protocols, with users noting deeper sleep and more vivid dreams before any body composition changes appear.
- Gradual body composition improvement by months 2 to 3. Community reports describe reduced abdominal fat and improved muscle fullness, consistent with GH-mediated lipolysis and anabolic signaling observed in GRF(1-29) infusion literature.
- Short half-life allows fine-grained protocol control. If side effects appear, the compound clears within hours. Compare that to CJC-1295 DAC, which sustains GH elevation for days after a single injection.
CJC-1295 (No DAC): Science vs Community Consensus
No dedicated clinical trials exist for the no-DAC / Mod GRF 1-29 form.
Read the evidence (key study, limitations)
Mechanism confirmed via GHRH receptor binding analog studies. Human GRF(1-29) infusion data (1990s) confirms pulsatile GH release. The 100 mcg dosing convention is extrapolated from D-Ala2 analog PK studies and community experience, not from a Mod GRF 1-29-specific human trial. The ~30 min half-life is a community estimate; no human study has measured it. Academic research since 2020 has pivoted to higher-potency GHRH analogs; no new no-DAC-specific trial is in progress.
Corpas et al. 1992 (PMID 1379256): GHRH(1-29) twice daily reversed the decreased GH and IGF-1 levels in old men; closest proxy for no-DAC human dosing. Soule et al. 1994 (PMID 7962295): D-Ala2-GHRH(1-29)NH2 by IV infusion in 10 men, disappearance half-time 6.7 min vs 4.3 min for GHRH(1-29)NH2; no SC data.
Zero completed Phase I/II/III trials for the no-DAC form. Dosing entirely community-derived. The ~30 min half-life is a community estimate: no PK study in humans for this specific compound. No long-term safety data.
Considered the gold-standard GHRH analog for pulsatile GH release when stacked with Ipamorelin.
Read the reports (what users report 5, common issues 5)
Preferred over CJC-1295 DAC for pulse control and avoided GH bleed. Multiple daily injections and strict fasting windows are the main friction points.
- Natural pulsatile GH release: physiologically aligned vs. DAC tonic stimulation
- Clean hormonal profile: no cortisol or prolactin elevation with Ipamorelin pairing
- Improved sleep quality and depth within weeks 1–2
- Short half-life allows fine-grained control: easy to stop if side effects emerge
- Body composition improvement (fat loss, muscle fullness) by months 2–3
- Multiple daily injections required (vs. DAC weekly): common drop-off cause
- Strict 2-hour fasting window before every injection: non-negotiable for GH pulse
- Mild water retention (less than DAC but present, especially at higher frequency)
- IGF-1 often stays near-unchanged without Ipamorelin: solo use discouraged
- Product quality highly variable; purity as low as 68.75% documented (Finnrick 2024–2026)
Science and community agree on GHRH receptor mechanism and pulsatile GH release rationale. Community 100 mcg dosing convention is plausible but not clinically validated for this specific compound: it derives from receptor saturation modeling and analog studies. Science has zero completed trials for the no-DAC form. Fasting requirement is mechanistically sound (insulin raises somatostatin). Cycling rationale is community-derived with no direct clinical confirmation of desensitization at these doses.
CJC-1295 (No DAC) Dosage Guide
Mod GRF 1-29 needs to be co-injected with a GHRP to do much. Solo use rarely moves IGF-1 meaningfully; the community discourages it. Ipamorelin at 100 mcg co-injected is the standard pairing.
Reconstitution math for common vial sizes. A 2 mg vial with 2 mL bacteriostatic water gives you 1,000 mcg/mL. A 100 mcg dose is 10 units on an insulin syringe (0.1 mL). A 5 mg vial with 2 mL bacteriostatic water gives you 2,500 mcg/mL. A 100 mcg dose is 4 units (0.04 mL); a 200 mcg dose is 8 units (0.08 mL).
The fasting window is non-negotiable. Two hours minimum with no food before injection; 30 minutes after. Insulin raises somatostatin, which shuts down the GH pulse completely. This is the number-one troubleshooting issue when users report no IGF-1 movement after weeks on protocol. Check fasting compliance before blaming the peptide.
Abdominal subcutaneous injection absorbs faster than thigh or flank. For a compound with a 30-minute active window, that speed matters.
Cycling Protocol
Cycle to prevent pituitary desensitization. Some users run 5 days on, 2 days off weekly.
Chronic daily GHRH stimulation can shift somatostatin tone (the primary inhibitory counterbalance to GH release) and reduce pituitary somatotroph responsiveness over time. When stacked with Ipamorelin, GHS-R1a desensitization from the GHRP component adds a second desensitization mechanism. Community consensus and analog literature support 12-week on / 4-week off cycling. The short half-life (~30 min, estimated) means receptor exposure is only during the brief post-injection window, desensitization is slower than with the DAC form, but 16+ weeks of daily use without a break has produced reported diminishing returns in community experience.
- Diminishing sleep improvement effect after week 10–12
- IGF-1 levels plateauing or declining despite continued dosing
- Facial flushing response weakening (early indicator of blunted pituitary response)
- Reduced post-injection recovery sensation vs. early cycle
Or use the universal Peptide Calculator for any peptide.
CJC-1295 (No DAC) Protocols by Goal
Expected: Improved sleep quality within 1–2 weeks; mild recovery improvement by weeks 3–4; modest body composition changes by months 2–3
Monitor: Baseline IGF-1 before starting; recheck at week 6 and week 12. Fasting glucose at baseline.
How to Inject CJC-1295 (No DAC)
- 1Step 1
Pull your vial of lyophilized Mod GRF 1-29 from refrigeration (2 to 8 degrees C). Let it reach room temperature for a few minutes. Don't shake it.
- 2Reconstitute with bacteriostatic water
For a 2 mg vial, add 2 mL (this gives 1,000 mcg/mL). For a 5 mg vial, add 2 mL (this gives 2,500 mcg/mL). Aim the stream against the glass wall of the vial. Let the powder dissolve; gentle swirling is fine.
- 3Draw your dose using a 29 to 31 gauge insulin syringe
For 100 mcg from a 2 mg/2 mL vial, draw to the 10-unit mark (0.1 mL). For 100 mcg from a 5 mg/2 mL vial, draw to the 4-unit mark (0.04 mL). For 200 mcg from a 5 mg/2 mL vial, draw to the 8-unit mark (0.08 mL).
- 4Step 4
If stacking with Ipamorelin (recommended), draw both peptides into the same syringe. Order doesn't matter for subcutaneous injection.
- 5Step 5
Pinch a fold of skin on the lower abdomen, about 2 inches from the navel. Insert the needle at a 45-degree angle. Inject slowly. Release the skin fold.
- 6Step 6
Timing: inject 30 to 60 minutes before bed on a fully fasted stomach (2 or more hours since last food). Don't eat for 30 minutes after injection. An optional second injection can be taken in the morning on waking (fasted) or post-workout (fasted).
- 7Rotate injection sites each time to prevent lipodystrophy
Store the reconstituted vial at 2 to 8 degrees C and use within 3 to 4 weeks.
CJC-1295 (No DAC) Stacking Protocols
Works With
Primary and near-universal stack. GHRH (Mod GRF) + GHRP (Ipamorelin) activates dual pituitary pathways (GHRHR + GHS-R1a); community reports describe a larger combined GH pulse. Ipamorelin selected for selectivity: no cortisol, ACTH, or prolactin elevation. Co-injected at same time.
100 mcg Mod GRF 1-29 + 100 mcg Ipamorelin SC, 1–2× daily, fasted
Pre-mixed 5mg/5mg blend combines both components into one injection. Functionally identical to separate dosing. Convenience-focused users prefer the blend.
200–300 mcg total (100–150 mcg each component) SC 1–2× daily, fasted
Alternate GHRP that community reports favor for a stronger GH pulse in performance protocols. No human study has compared it with Ipamorelin; in swine, GHRP-2 was more potent per dose, but Ipamorelin reached the higher GH peak (PMID 9849822). It brings mild cortisol and prolactin co-elevation. Used when maximum GH output is the goal.
100 mcg Mod GRF 1-29 + 100 mcg GHRP-2 SC, 2–3× daily, fasted
Concurrent recovery stack (separate mechanism, not GH pathway). GH elevation from Mod GRF complements BPC-157 tissue repair signaling for injury recovery and connective tissue support.
Avoid
Redundant GHRH pathway: both Mod GRF 1-29 and Sermorelin act on the same GHRHR receptor. No additive benefit demonstrated; simply competes at the same binding site. Choose one or the other.
Combining DAC and no-DAC forms creates overlapping GHRHR stimulation with mismatched half-lives. The DAC form provides sustained tonic GHRH exposure that defeats the pulsatile rationale of no-DAC. No documented benefit; increased receptor desensitization risk.
Combining GH secretagogues with exogenous HGH saturates the GH axis and suppresses endogenous pulsatility. Eliminates the primary rationale for using secretagogues (axis preservation). Dramatically increases IGF-1 overshoot risk.
Do not combineHow much does CJC-1295 (No DAC) cost?
Typical price
$6.99 to $9.50 per mg
Middle half of 54 US prices for 5 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
CJC-1295 (No DAC) Side Effects
The biggest safety concern with CJC-1295 (No DAC) is that zero completed clinical trials exist for this specific compound. Every side effect profile is extrapolated from analog studies and community experience. That context matters for everything below.
Facial flushing is the most immediately noticeable effect. It typically hits within 5 to 15 minutes of injection, feels like a warm rush to the face and ears, and resolves within 30 to 60 minutes. This is a vasodilatory response from the GH pulse itself, not an allergic reaction. Community reports treat it as a sign the peptide is active. Reducing the dose lessens the intensity.
Headache and dizziness occur in some users, usually during the first week. These tend to be transient and resolve as the body adjusts to regular GH pulses. Injection site redness and irritation are typical of any subcutaneous peptide; rotating sites prevents local tissue issues.
Water retention is the side effect that gets the most community attention at higher dose frequencies. GH promotes sodium and water reabsorption. Mild puffiness around the hands and face is common, especially at twice-daily dosing. If retention becomes pronounced (visible edema, tight rings, swollen ankles), reduce frequency before reducing dose. Persistent edema warrants checking IGF-1 levels.
Carpal tunnel symptoms (tingling, numbness in the hands, grip weakness) signal excessive GH-mediated fluid retention compressing the median nerve. This is a dose-dependent effect. Reduce dose immediately if it appears. If symptoms persist beyond one week at a lower dose, stop entirely and allow four or more weeks of recovery.
GH release antagonizes insulin action. Anyone with diabetes, prediabetes, or insulin resistance should monitor fasting glucose carefully. Teichman et al. (2006)[4] documented insulin sensitivity effects with the DAC form; the no-DAC form carries the same mechanistic risk at lower magnitude due to shorter exposure.
GH promotes cell proliferation. Active cancer or a history of malignancy is a contraindication. Pregnancy and breastfeeding are absolute contraindications. Untreated hypothyroidism can blunt the GH response entirely and should be addressed before starting.
Product quality adds an underappreciated risk layer. Finnrick Analytics tested 244 samples from 47 companies and found purity ranging from 68.75% to 99.95%. Underdosed or degraded product produces unpredictable responses; the no-DAC form (MW approximately 3,367 Da) is sometimes substituted with the DAC form (MW approximately 3,647 Da) in low-quality products.
When to see a doctor: carpal tunnel symptoms that don't resolve with dose reduction, persistent unexplained edema, fasting glucose above 125 mg/dL, or any new numbness or paresthesia.
Common Issues & Solutions
No IGF-1 change after 8 weeks: Most common cause is eating within 2 hours before injection: insulin raises somatostatin and blunts the GH pulse completely. Check fasting compliance first, then product quality (a batch-specific CoA is the only check).
Facial flushing within minutes of injection: Expected vasodilatory response from GH release. Usually peaks at 5–15 minutes, resolves within 30–60 minutes. Reduce dose if severe; does not indicate an allergic reaction in most cases.
Water retention / puffiness: Common with any GH secretagogue. Reduce injection frequency before reducing dose. If significant edema persists, stop and check IGF-1 levels: may indicate excessive GH response.
Diminishing response after week 8–10: Consistent with somatostatin tone accumulation and possible GHS-R1a desensitization (from Ipamorelin component). Consider cycling off 2 weeks early rather than pushing through. Ensure 4-week off period before restarting.
Tingling or numbness in hands: Early carpal tunnel symptom from GH-mediated fluid retention. Reduce dose or frequency immediately. If it persists more than 1 week at reduced dose, discontinue and allow 4+ weeks recovery.
Ask AI about this page
Ask AI for a second opinion on CJC-1295 (No DAC) dosing and side effects
Contraindications
- Active cancer or history of malignancy: GH promotes cell proliferation
- Diabetes mellitus: GH antagonizes insulin and may worsen blood sugar control
- Pregnancy or breastfeeding
- Active pituitary tumors or intracranial neoplasms
- Known hypersensitivity to GHRH analogs
- Untreated hypothyroidism: may blunt GH response
Drug Interactions
- Insulin and oral hypoglycemics: GH release antagonizes insulin action; monitor blood glucose closely
- Corticosteroids: chronic use may blunt GH response and reduce efficacy
- Other GH secretagogues (GHRP-2, GHRP-6, Ipamorelin): additive GH release increases side effect risk; use caution when stacking
- Thyroid hormones: GH can accelerate T4-to-T3 conversion; monitor thyroid function
- CYP3A4-metabolized drugs: GH may alter hepatic clearance rates
- Redundant GHRH pathway: both Mod GRF 1-29 and Sermorelin act on the same GHRHR receptor. No additive benefit demonstrated; simply competes at the same binding site. Choose one or the other.
- Combining DAC and no-DAC forms creates overlapping GHRHR stimulation with mismatched half-lives. The DAC form provides sustained tonic GHRH exposure that defeats the pulsatile rationale of no-DAC. No documented benefit; increased receptor desensitization risk.
Product Quality
Finnrick Analytics tested 244 CJC-1295 samples from 47 companies (Dec 2024–Mar 2026). Purity ranged from 68.75% (5th percentile) to 99.95% (95th percentile). Quantity accuracy diverges up to ±100% from label. No GMP requirement applies to "research use only" products. The no-DAC form (MW ~3.4 kDa) is frequently mislabeled or substituted with CJC-1295 DAC (MW ~3.6 kDa) in low-quality products.
- A credible CoA is batch-specific, names the third-party lab and lists a certificate number (a generic in-house document is not)
- Independent batch testing measures purity and identity for one lot; the result does not carry over to other batches
- Mislabeling red flag: "no-DAC" product sold alongside weekly-dose protocols or 1mg vials may actually be the DAC form
- CoA should specify peptide MW ~3,367 Da (no-DAC form): DAC form is ~3,647 Da
- If IGF-1 is not moving after 6 weeks of strict fasting compliance, suspect underdosed or degraded product before increasing dose
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 | Baseline before starting; repeat at week 6 and week 12 | Age-adjusted normal range (not supraphysiological). Flag if above upper limit of normal. |
| IGFBP-3 | Baseline; repeat at week 12 | Age-adjusted normal range |
| Fasting glucose | Baseline; repeat at week 6 and week 12 | <100 mg/dL (normal); 100–125 mg/dL warrants dose reduction and closer monitoring |
| Thyroid (TSH, fT3, fT4) | Baseline; repeat at week 12 if symptoms emerge | Not listed |
Primary efficacy marker for GH axis activation. Confirms peptide quality and dosing adequacy. Detects over-response requiring dose reduction.
Low IGFBP-3 with elevated IGF-1 = elevated free IGF-1 → increased cancer signaling risk. IGF-1 alone is insufficient for safe GH axis monitoring.
GH release antagonizes insulin action. Relevant especially in pre-diabetic or insulin-resistant individuals.
GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response; GH supplementation can unmask subclinical hypothyroidism.
CJC-1295 (No DAC) Before and After
Improved sleep quality and more vivid dreams. Some users report mild water retention and occasional facial flushing after injection.
Noticeable improvements in recovery time between workouts. Skin hydration and texture begin to improve. Increased morning energy.
Body composition shifts become apparent: reduced abdominal fat and improved muscle tone. Joint and connective tissue comfort improves.
Full anti-aging and recovery benefits are established. Sustained fat loss, better exercise capacity, and improved skin elasticity.
Benefits plateau at this stage. Cycle off for 4 weeks to maintain pituitary receptor sensitivity before restarting protocol.
What to Expect
Week 1 to 2: Sleep changes come first. Most users report deeper sleep and more vivid dreams within the first week of consistent bedtime dosing. Mild facial flushing after injection is normal and resolves in under an hour. Some water retention appears early on.
Weeks 3 to 6: Recovery speed improves. Muscle soreness between workouts decreases noticeably. Skin hydration gets better. IGF-1 should be measurably raised by week 4 if fasting compliance is strict and product quality is good. Energy tends to pick up through this stretch.
Weeks 6 to 12: Body composition shifts become visible. Reduced abdominal fat and improved muscle fullness are the most commonly reported changes in this window. Skin elasticity improves. Joint comfort gets better. Some users plateau around week 10 to 12 as somatostatin tone accumulates and receptor sensitivity declines.
Month 4 and beyond (off cycle): The compound clears within hours of the last injection; no GH bleed like the DAC form. Pituitary receptor sensitivity recovers within 2 to 4 weeks. Benefits are largely retained for 4 to 6 weeks post-cycle. Body composition regresses gradually over 6 to 8 weeks without the protocol. Most users restart after the standard 4-week off period.
Detailed Timeline: Science vs Community
GH pulse augmentation confirmed immediately in analog studies; IGF-1 elevation begins within days of consistent dosing.
Improved sleep quality and more vivid dreams are the first-reported effects. Some users note mild facial flushing post-injection and mild water retention.
IGF-1 should be measurably elevated by week 4 with consistent protocol. GH promotes anabolic signaling in connective tissue.
Faster workout recovery, reduced muscle soreness, improved skin hydration. Early lean tissue quality improvement noted. Energy generally improves.
GH/IGF-1 axis-mediated lipolysis and anabolic signaling produce measurable body composition changes over 8–12 weeks in GRF(1-29) infusion literature.
Visible reduction in abdominal fat, improved muscle fullness, better skin elasticity. Joint and connective tissue improvement. Some users plateau at week 10–12.
Short half-life (~30 min, estimated) means compound clears within hours of last injection. No prolonged GH bleed unlike CJC-1295 DAC. Pituitary receptor sensitivity should recover within 2–4 weeks off.
Benefits largely retained for 4–6 weeks post-cycle. Some regression in body composition over 6–8 weeks without protocol. Most users restart after the 4-week off period.
Pharmacokinetics
Source: No human PK study of Mod GRF 1-29; ~30 min is a community estimate. Closest measured analog: D-Ala2-GHRH(1-29)NH2, 6.7 min disappearance half-time during IV infusion in 10 men (Soule et al. 1994, PMID 7962295)
Pharmacokinetics: Active Dose Over Time
t½ = ~30 min (estimated, never measured in humans)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is CJC-1295 (No DAC) Legal?
CJC-1295 without DAC (Mod GRF 1-29) is sold as a research chemical in the United States. It has no FDA approval for any indication. FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against adding CJC-1295 (free base and acetate) to the 503A bulks list on December 4, 2024. The vote is advisory, and FDA has not ruled on the listing. CJC-1295 is not on the 503A bulks list (21 CFR 216.23). FDA's Category 2 page lists CJC-1295 as withdrawn by its nominators and notes serious adverse events, including increased heart rate and a systemic vasodilatory reaction.
For athletes, both CJC-1295 and Ipamorelin appear on the WADA prohibited list under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Anti-doping labs have built urine tests for CJC-1295 using spiked samples [5], and one was validated to WADA standards [6].
It is sold online under "for research purposes only" labeling. No GMP manufacturing requirement applies. This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider CJC-1295 (No DAC)
- Adults over 30 experiencing age-related GH decline (somatopause)
- Athletes and bodybuilders seeking improved recovery and body composition
- Individuals looking to improve sleep quality and depth
- Post-injury patients wanting faster tissue repair
- Those who prefer natural pulsatile GH release over sustained elevation
Related Peptides
What Changed for CJC-1295 (No DAC)
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]GH-Releasing Hormone-(1-29) Twice Daily Reverses Decreased GH and IGF-I Levels in Old Men (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Incorporation of D-Ala2 in GHRH-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men (Soule et al., J Clin Endocrinol Metab 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Ipamorelin, the first selective growth hormone secretagogue (Raun et al. 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Advances in the detection of growth hormone releasing hormone synthetic analogs (Memdouh et al., Drug Test Anal 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry (J Pharm Biomed Anal 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Identification of CJC-1295 as a Long-Lasting GRF Analog via hGRF(1-29)-Albumin Bioconjugates (opens in a new tab)PubMed 15817669PubMed
- Pulsatile Secretion of GH Persists During Continuous Stimulation by CJC-1295 (opens in a new tab)PubMed 17018654PubMed
- Effects of a GHRH Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men (opens in a new tab)PubMed 20943777PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is CJC-1295 (No DAC)?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 300–600+. Community mentions on Reddit: ~300–600+ (r/peptides); "CJC-1295" broadly is one of the top. Open r/peptides (opens in a new tab).
3 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.